LegoChem Biosciences Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 144

Employees

  • Stock Symbol
  • 141080

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $37.93
  • (As of Friday Closing)

LegoChem Biosciences General Information

Description

LegoChem Biosciences Inc develops new drugs through research. The Company provides business research services, manufacturing and sale of compounds, and drug evaluation.

Contact Information

Website
www.legochembio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Primary Office
  • 10, Gukjegwahak 10-ro
  • Yuseong-gu
  • Daejeon
  • South Korea
+82 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LegoChem Biosciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$37.93 $34.91 $23.88 - $38.51 $1B 26.4M 301K -$2.45

LegoChem Biosciences Financials Summary

In Thousands,
USD 		TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 634,676 711,579 996,008 1,454,933
Revenue 26,173 25,858 28,074 41,834
EBITDA (66,018) (36,828) (15,982) (5,819)
Net Income (63,061) (34,898) (20,422) (5,917)
Total Assets 148,302 199,959 246,411 124,585
Total Debt 9,014 9,699 10,310 3,655
Public Fundamental Data provided by Morningstar, Inc. disclaimer

LegoChem Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore LegoChem Biosciences‘s full profile, request access.

Request a free trial

LegoChem Biosciences Patents

  • 192

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 18

    Granted

  • 6

    Pending

  • 000

    Expiring in next 12 mo

LegoChem Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022250810-A1 Antibody-drug conjugate including antibody against human cldn18.2, and use thereof Pending 30-Mar-2021 00000000000
CA-3213985-A1 Antibody-drug conjugate including antibody against human cldn18.2, and use thereof Pending 30-Mar-2021 00000000000
EP-4086268-A1 Pyrrolobenzodiazepine derivative and ligand-linker conjugate thereof Pending 31-Dec-2019 000000000
US-20230310640-A1 Pyrrolobenzodiazepine derivative and ligand-linker conjugate thereof Pending 31-Dec-2019 00000000000
JP-2023508508-A Pyrrolobenzodiazepine derivatives and their ligand-linker conjugates Pending 31-Dec-2019 C07H15/26
To view LegoChem Biosciences’s complete patent history, request access »

LegoChem Biosciences Executive Team (7)

Name Title Board Seat Contact Info
Yong-zu Kim Ph.D Founder, Chief Executive Officer & Chairman
Sejin Park Chief Financial Officer & Senior Vice President
Young-Lag Cho Ph.D Co-Founder & Chief Development Officer
YongSoo Yoon Director, Marketing
Jeiwook Chae Ph.D Chief Business Development Officer
You’re viewing 5 of 7 executive team members. Get the full list »

LegoChem Biosciences Board Members (2)

Name Representing Role Since
Pil-jae Maeng LegoChem Biosciences Board Member 000 0000
Yong-zu Kim Ph.D LegoChem Biosciences Founder, Chief Executive Officer & Chairman 000 0000
To view LegoChem Biosciences’s complete board members history, request access »

LegoChem Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LegoChem Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore LegoChem Biosciences‘s full profile, request access.

Request a free trial

LegoChem Biosciences Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
S-Alpha Therapeutics 01-Feb-2020 000000000 00000 Drug Discovery
Geom Therapeutics 07-Jul-2016 0000000000 Drug Discovery 00000 000
Khanmed 21-Dec-2015 Merger/Acquisition 000.00 Distributors (Healthcare)
To view LegoChem Biosciences’s complete investments and acquisitions history, request access »

LegoChem Biosciences ESG

Risk Overview

Risk Rating

Updated July, 12, 2023

39.38 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,708

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 884

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 418

Rank

00.00

Percentile

To view LegoChem Biosciences’s complete esg history, request access »

LegoChem Biosciences Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
Geom Therapeutics 07-Jul-2016 000000000000000000 Completed
  • 00000000 000000000
To view LegoChem Biosciences’s complete exits history, request access »